Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809
Sponsor: Boehringer Ingelheim
Summary
To assess the exposure of BI 425809 in cerebrospinal fluid relative to plasma as well as safety and tolerability, and to evaluate the effect of different doses of BI 425809 on biomarkers levels in cerebrospinal fluid.
Official title: Non-randomised, Open Label, Sequential-group Study to Assess the Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809 in Healthy Male Volunteers
Key Details
Gender
MALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2015-02-23
Completion Date
2015-06-19
Last Updated
2026-05-01
Healthy Volunteers
Yes
Conditions
Interventions
BI 425809
Tablet
Locations (1)
1346.3.32001 Boehringer Ingelheim Investigational Site
Antwerp, Belgium